ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,469.30
0.39%
Dow Jones
39,112.16
0.00%
US Dollar vs MXN
18.2693
0.79%
Brent Oil
84.675
0.58%
Bitcoin
61,429.82
-0.62%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. 4D Pharma PLC (LBPS)

  7. 4D Pharma PLC (LBPS) Noticias

LBPS

4D Pharma (LBPS)

4D Pharma PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:LBPS
FechaHoraFuenteTítuloSímboloCompañía
03/01/202311:10Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
19/07/202210:49Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:LBPS4D Pharma PLC
28/06/202212:50Business Wire4D pharma plc (“4D pharma”) Receives Notice of Delisting From NasdaqNASDAQ:LBPS4D Pharma PLC
27/06/202207:15TipRanksWhat Made Chardan Capital Downgrade 4d Pharma’s Stock?NASDAQ:LBPS4D Pharma PLC
24/06/202214:32TipRanksLadenburg Thalmann & Co. Downgrades 4d Pharma (LBPS) to HoldNASDAQ:LBPS4D Pharma PLC
24/06/202213:41Business WireUpdate on Suspension of TradingNASDAQ:LBPS4D Pharma PLC
26/05/202216:30Business Wire4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:LBPS4D Pharma PLC
19/05/202215:30Business Wire4D pharma to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:LBPS4D Pharma PLC
17/05/202206:00Business Wire4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International ConferenceNASDAQ:LBPS4D Pharma PLC
29/04/202205:34Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LBPS4D Pharma PLC
31/03/202216:27Business Wire4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022NASDAQ:LBPS4D Pharma PLC
28/03/202216:29Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3/a)NASDAQ:LBPS4D Pharma PLC
23/03/202206:00Business Wire4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell CarcinomaNASDAQ:LBPS4D Pharma PLC
02/03/202216:26Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:LBPS4D Pharma PLC
28/02/202215:34Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:LBPS4D Pharma PLC
23/02/202206:00Business Wire4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines SummitNASDAQ:LBPS4D Pharma PLC
22/02/202206:00Business Wire4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s DiseaseNASDAQ:LBPS4D Pharma PLC
18/02/202216:03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:LBPS4D Pharma PLC
18/02/202216:02Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:LBPS4D Pharma PLC
28/01/202205:45TipRanksLadenburg Thalmann & Co. Thinks 4d Pharma’s Stock is Going to RecoverNASDAQ:LBPS4D Pharma PLC
27/01/202206:00Business Wire4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of AsthmaNASDAQ:LBPS4D Pharma PLC
20/01/202206:00Business Wire4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004NASDAQ:LBPS4D Pharma PLC
20/01/202205:45TipRanksLadenburg Thalmann & Co. Maintains a Buy Rating on 4d Pharma (LBPS)NASDAQ:LBPS4D Pharma PLC
05/01/202206:00Business Wire4D pharma to Present at the H.C. Wainwright BioConnect ConferenceNASDAQ:LBPS4D Pharma PLC
03/01/202206:00Business Wire4D pharma appoints John Doyle as Chief Financial OfficerNASDAQ:LBPS4D Pharma PLC
13/12/202106:00Business Wire4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of AsthmaNASDAQ:LBPS4D Pharma PLC
09/12/202106:00Business Wire4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021NASDAQ:LBPS4D Pharma PLC
15/11/202107:00GlobeNewswire Inc.CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of DirectorsNASDAQ:LBPS4D Pharma PLC
11/11/202106:00Business Wire4D pharma to Participate in Jefferies London Healthcare ConferenceNASDAQ:LBPS4D Pharma PLC
12/10/202106:00Business Wire4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics SummitNASDAQ:LBPS4D Pharma PLC
 Showing the most relevant articles for your search:NASDAQ:LBPS

Su Consulta Reciente

BIT
UB486L
Unicredit Bank
LSE
36SI
Co.st.gob. 26
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados